Published in Blood Weekly, February 1st, 2001
"The optimum regimen of epoetin alfa for prevention of allogeneic blood transfusion is unknown," according to B.G. Feagan and colleagues at the John P. Robarts Research Institute in Ontario, Canada. So, they conducted a study in patients undergoing hip arthroplasty to pursue this question.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.